Cipla. has filed a patent for a method and composition for treating pulmonary hypertension using desipramine or its salt. The method involves administering the composition to patients in need, potentially offering a new treatment option for pulmonary arterial hypertension. GlobalData’s report on Cipla gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Cipla, Peptide pharmacophores was a key innovation area identified from patents. Cipla's grant share as of January 2024 was 38%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment of pulmonary hypertension using desipramine or its salt
See Also:
A recently filed patent (Publication Number: US20240016814A1) discloses a method for treating pulmonary hypertension in patients by administering a composition containing desipramine or its pharmaceutically acceptable salt. The method specifies that the patient should have a resting pulmonary arterial pressure greater than 14 mm Hg, with desipramine administered in an amount effective to lower the pressure to a specified level. The patent also includes provisions for administering additional agents alongside desipramine to treat pulmonary hypertension effectively.
Furthermore, the patent describes a pharmaceutical composition comprising desipramine or its salt along with additional agents for treating pulmonary hypertension. The composition includes various classes of agents such as phosphodiesterase inhibitors, calcium channel blockers, and prostacyclin pathway agonists. Additionally, a kit containing desipramine or its salt, along with the mentioned additional agents, is also part of the patent claims. This kit aims to provide a comprehensive solution for treating pulmonary hypertension by combining desipramine with other effective agents in a convenient package for patient use.
To know more about GlobalData’s detailed insights on Cipla, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
